Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 26;89(13):1355-1364.
doi: 10.1212/WNL.0000000000004415. Epub 2017 Aug 25.

A natural history study of X-linked myotubular myopathy

Affiliations

A natural history study of X-linked myotubular myopathy

Kimberly Amburgey et al. Neurology. .

Abstract

Objective: To define the natural history of X-linked myotubular myopathy (MTM).

Methods: We performed a cross-sectional study that included an online survey (n = 35) and a prospective, 1-year longitudinal investigation using a phone survey (n = 33).

Results: We ascertained data from 50 male patients with MTM and performed longitudinal assessments on 33 affected individuals. Consistent with existing knowledge, we found that MTM is a disorder associated with extensive morbidities, including wheelchair (86.7% nonambulant) and ventilator (75% requiring >16 hours of support) dependence. However, unlike previous reports and despite the high burden of disease, mortality was lower than anticipated (approximate rate 10%/y). Seventy-six percent of patients with MTM enrolled (mean age 10 years 11 months) were alive at the end of the study. Nearly all deaths in the study were associated with respiratory failure. In addition, the disease course was more stable than expected, with few adverse events reported during the prospective survey. Few non-muscle-related morbidities were identified, although an unexpectedly high incidence of learning disability (43%) was noted. Conversely, MTM was associated with substantial burdens on patient and caregiver daily living, reflected by missed days of school and lost workdays.

Conclusions: MTM is one of the most severe neuromuscular disorders, with affected individuals requiring extensive mechanical interventions for survival. However, among study participants, the disease course was more stable than predicted, with more individuals surviving infancy and early childhood. These data reflect the disease burden of MTM but offer hope in terms of future therapeutic intervention.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Survival and burden of disease in an MTM cohort
(A) Survival of participants over the course of the study. For those who died, age and cause of death are summarized in the table to the right of the graph. Twelve of 50 patients in our cohort were deceased, and the average age at death was 6 years 10 months. Note that 3 died during the longitudinal study, including 1 individual who died 2 months after survey completion. (B) Burden of disease (respiratory, feeding, and ambulation support requirements). Breakdown of technology support required, including wheelchair dependence, feeding tube, and ventilation. Forty-eight of 50 patients with MTM had some technology dependence, and 37 of 48 were wheelchair, ventilator, and tube feed dependent. (C) Change in respiratory status during the 1-year longitudinal survey (listed as percent of the total cohort, n = 33). The majority of individuals had either no change or small fluctuations in support. Small fluctuations were defined as 1 or 2 increases or decreases in time on ventilation that lasted <3 months. Frequent changes were defined as ≥3 periods (≤3 months) of increased or decreased ventilator setting requirements. Changes in time needing ventilation sustained for at least 4 months are indicated as increased requirements or sustained improvement. (D) Breakdown of the extent of feeding support, respiratory support, and highest motor function at the time of survey completion. G-tube = gastrostomy tube; MTM = myotubular myopathy.
Figure 2
Figure 2. Perinatal evaluation score (PES) and neonatal respiratory support in relation to patient outcome
(A) Breakdown of PES and patient outcome. PES was defined by McEntagart et al. Individuals with scores for at least 4 of the 6 PES factors were included. Most individuals in our cohort were in the severe or moderate categories for PES (PES <3 of 6 or <50%). There was no obvious correlation between PES and need for future respiratory support and survival. PES was determined by 6 factors: delivery (normal = 1, abnormal = 0), fetal movement (normal = 1, weak or absent = 0), polyhydramnios (no = 1, yes = 0), tendon reflexes at birth (present = 1, absent = 0), joint contractures or club feet (no = 1, yes = 0), and intubation at birth (no = 1, yes = 0). All 34 had scores (0 or 1) for at least 4 of 6 factors. (B) Flow diagram of respiratory requirement at birth and patient outcome. Modeled after the flow diagram in McEntagart et al. Sufficient perinatal data were available for 35 individuals with MTM in the study. Note that essentially all individuals who required respiratory support at birth went on to need it after the neonatal period. While a small sample size, 2 of 3 who did not require breathing support at birth were ventilator free at study completion (ages 2 years 2 months, 32 years 10 months, and 42 years 4 months). XLMTM = X-linked myotubular myopathy.
Figure 3
Figure 3. Genotype–phenotype correlations
Genetic testing results were available for 35 individuals. Twenty-seven unique mutations were identified. For genotype–phenotype assessment, mutations were categorized as nonsense (n = 17), missense (n = 10), or splice site (n = 8). Of note, 1 recurrent missense mutation (R69C in the PH-GRAM domain) has been shown to alter splicing (Pierson et al.). (A) Mutation type and location. Mutations in MTM1 were found throughout the gene, and there was no obvious clustering in sections of the MTM1 gene coding for the known functional domains. Protein domain locations were defined by Laporte et al. (B) Mutation type and location in relationship to respiratory requirement. Because nearly all individuals required ventilatory support, there was no clear correlation between ventilation and mutation type, although a higher proportion of individuals with missense mutations did not need invasive support (4 of 10 missense on noninvasive support vs 0 of 17 nonsense and 1 of 8 splice site). (C) Mutation location and motor function. Other than 1 individual with a nonsense mutation, only individuals with missense mutations achieved the ability to ambulate independently (3 of 10).
Figure 4
Figure 4. Hospitalizations and surgeries during a 1-year prospective study of myotubular myopathy
We tracked hospital visits (ER and admissions) and surgeries during our 1-year prospective analysis. Twenty-four of 33 individuals in the study required at least 1 of these services (pie chart, top left). There were 38 ER visits (pie chart, top right, listed by chief complaint), with fever and infection the most common reasons. Infections included pneumonia, pseudomonas, enterovirus, and rhinovirus. aRespiratory issues included respiratory distress, lung collapse, and high CO2 levels. bEquipment issues included ventilator malfunction, mucous plugs, and leaky gastrostomy tubes. cOther reasons for ER visits included drug allergy, power chair accident, postsurgical hip pain, and inability to urinate. There were 13 emergent hospitalizations (i.e., not scheduled or elective admissions), with infection the overwhelmingly most common reason for admission (pie chart, bottom right). There were 27 elective surgical procedures reported, with ear tube placement (i.e., myringotomy tube placement) the most common surgery. ER = emergency room.

Comment in

References

    1. Laporte J, Hu LJ, Kretz C, et al. . A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175–182. - PubMed
    1. Das S, Dowling J, Pierson CR. X-linked centronuclear myopathy. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews. Seattle, WA: University of Washington; 1993–2017.
    1. Childers MK, Joubert R, Poulard K, et al. . Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014;6:220ra210. - PMC - PubMed
    1. Lawlor MW, Armstrong D, Viola MG, et al. . Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet 2013;22:1525–1538. - PMC - PubMed
    1. Cowling BS, Chevremont T, Prokic I, et al. . Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest 2014;124:1350–1363. - PMC - PubMed

MeSH terms